These are good times for investors to start thinking about putting together shopping lists for speculative healthcare stocks, as the market has been bailing out on not only biotechs but also speculative med-techs. AtriCure (NASDAQ:ATRC) isn't speculative in many important respects, as the company has approvals for its key products, but is still quite speculative insofar as the company's ability to convince doctors to adopt its surgical ablation approach and generate meaningful revenue and profits.
More Progress In The First Quarter
AtriCure continues to log respectable growth in its core businesses. Overall revenue rose 27% in the first quarter, good for a slight beat versus sell-side expectations. U.S. revenue rose 24% as 13% growth in ablation was augmented...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|